Navigation Links
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
Date:12/28/2012

FRIDAY, Dec. 28 (HealthDay News) For breast cancer patients prescribed tamoxifen to treat their disease, genetic traits affecting an enzyme in the liver are major players in determining the impact of the hormone therapy, new research suggests.

There's been debate in the scientific world for years over the role of genetic differences in the enzyme, known as CYP2D6. An estimated 5 percent to 7 percent of European and North American women have a trait that prevents the enzyme from working properly.

"Our findings confirm that, in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death," Dr. Matthew Goetz, a Mayo Clinic oncologist and lead author of the study that reported the findings, said in a Mayo Clinic news release.

The researchers tracked two groups of women: postmenopausal women with primary estrogen receptor-positive breast cancer who received tamoxifen for five years, and those took got the drug for two years followed by another drug, anastrozole, for three years.

Among those who took tamoxifen for five years, those whose genetic makeup prevented the enzyme from being able to process things were 2.5 times more likely to die or have their cancer return than those whose enzymes worked normally, the investigators found.

However, genetic traits involving the enzyme didn't seem to influence the fates of the women who switched to anastrozole, an aromatase inhibitor, after two years of tamoxifen, the study found.

"Switching from tamoxifen to an aromatase inhibitor may be one reason for the discrepant studies surrounding CYP2D6 and tamoxifen -- as information about whether a patient took an aromatase inhibitor after tamoxifen was not available in most of the prior studies," senior author Dr. James Ingle, of the Mayo Clinic, said in the news release.

Goezt thinks the study findings confirm that women should switch from tamoxifen to an aromatase inhibitor, or avoid tamoxifen altogether, if tests show they have the genetic trait that limits the metabolizing process.

The study was released online in advance of publication in an upcoming print issue of the journal Clinical Cancer Research.

More information

For more about breast cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCE: Mayo Clinic, news release, Dec. 26, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genes Linked to Autism Seem to Have Strong Tendency to Mutate
2. Scientists Now See 200 Genes Linked to Crohns Disease
3. Genes May Influence Effectiveness of Anti-Smoking Policies
4. Ethiopians and Tibetans thrive in thin air using similar physiology, but different genes
5. Valuable tool for predicting pain genes in people
6. A relationship between cancer genes and the reprogramming gene SOX2 discovered
7. Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
8. 1000 genomes study is guidebook to how genes vary
9. New findings on mens genes could alter interpretation of PSA test
10. Scientists step up hunt for bacterial genes tied to Lyme disease
11. Scientists to study the role genes play in treating TB
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Fresenius Vascular ... in minimally invasive techniques to treat and manage a wide range of vascular conditions, ... rebranding initiative. With more than 65 centers represented by more than 40 local brands, ...
(Date:6/20/2017)... ... June 20, 2017 , ... MindTouch , the leading ... proud to announce Touchpoints integrations. MindTouch Touchpoints easily integrate product documentation ... to provide a seamless customer experience. , Truly “plug and play,” Touchpoints are ...
(Date:6/20/2017)... ... June 20, 2017 , ... New, state-of-the-art magnetic ... is providing physicians with advanced capabilities for diagnosing and treating disease. , ... enabling doctors to get a more accurate look inside the patient’s body. The ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... systems industry has been selected as the partner of choice by Amtrak to ... railroad service that provides medium- and long-distance intercity service in the contiguous United ...
(Date:6/20/2017)... Pass, OR (PRWEB) , ... June 20, 2017 ... ... Recently, on her nationally syndicated radio program, The Sharon Kleyne Hour Power of ... EyeMist®, Kleyne launched right in to the world’s water crisis and how it ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... International plc (NASDAQ: ENDP ) announced today that ... Company in a fireside chat at Goldman Sachs, 38 th ... at 10:40 a.m. PT / 1:40 p.m. ET. The conference ... Palos Verdes, CA. A live webcast ... the Company,s website at http://www.endo.com/investors/overview . Participants should allow ...
Breaking Medicine Technology: